CAR T-cell success is exemplified by FDA-approval of the anti-CD19 CAR T-cell tisagenelcleucel for treatment of acute lymphoblastic leukemia (ALL) and axicabtagene ciloleucel for diffuse large B-cell lymphoma (DLBCL). The gene discussed is CD19; the disease is diffuse large B-cell lymphoma.